Why the study?
Do postchallenge hyperglycemia and LDL particles additively increase the risk of arterial stiffness in non-diabetic adults?
Do postchallenge hyperglycemia and LDL particles additively increase the risk of arterial stiffness in non-diabetic adults?
Postchallenge hyperglycemia and atherogenic LDL particles have an additive adverse effect on arterial stiffness in adults without clinical diabetes, highlighting a target for primary cardiovascular prevention.
May support combined glycemic-lipid assessment for stiffness risk in non-diabetics; leaves open causal effects and intervention benefits.
BACKGROUND: To determine the effects of post-challenge hyperglycemia potentiate low-density lipoprotein cholesterol (LDL) particles on the risk of arterial stiffness in non-diabetic adults. METHODS: During 2009-2011, 592 adults without clinical diabetes (fasting glucose <7.0 mmol/L) or known coronary heart disease or stroke were recruited. All subjects underwent standard 75-g oral glucose tolerance test (OGTT) after overnight fasting. The glucose area under curve (GluAUC) after OGTT was defined as the postchallenge glucose load. Levels of LDL-C and small dense LDL-C (sdLDL-C) were measured. Arterial stiffness in terms of brachial-ankle pulse wave velocity (baPWV) was also measured. RESULTS: The baPWV in tertile distributions were significantly associated with all conventional cardiovascular risk factors, LDL-C, and sdLDL-C. Multivariate logistic regression analyses revealed that LDL-C (or sdLDL-C) combined with one of the seven glycemic indices (glucose levels at 0, 30, 60, 90, and 120 min; GluAUC; HbA1C) was associated with arterial stiffness after covariates being adjusted. Further interaction analyses showed only concurrent higher levels of both glycemic indices and atherogenic LDL-C or sdLDL-C have significant risk for arterial stiffness. CONCLUSIONS: Additive effects of both postchallenge hyperglycemia and LDL subclass particles potentiate the risk of arterial stiffness. The adverse joint effects of hyperlipidemia and postchallenge hyperglycemia on subclinical cardiovascular function provide important information in primary prevention of cardiovascular disease in subjects without clinical diabetes.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: